Brief: GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
21/05/2024 14:06
May 21 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO PRESENTS POSITIVE PRECLINICAL DATA FROM PIPELINE
OF NKT
CELL MODULATORS IN DEVELOPMENT FOR THE TREATMENT OF SYSTEMIC
LUPUS ERYTHEMATOSUS (SLE)
* GRI BIO INC - COMPANY TARGETING IND FILING FOR GRI-0803 IN
Q3
2024 WITH TOPLINE DATA EXPECTED Q4 2024
* GRI BIO INC: COMPANY TARGETING IND FILING FOR GRI-0803 IN
Q3
2024 WITH TOPLINE DATA EXPECTED Q4 2024
Source text for Eikon: ID:nGNX2Lx7n8
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027